Aerie Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022 at 5:00 p.m. ET

Rhea-AI Summary

Aerie Pharmaceuticals (NASDAQ: AERI) will announce its first quarter 2022 financial results on May 5, 2022, post-market close. A conference call and webcast will take place at 5:00 p.m. ET to discuss the results and update on business developments. Aerie focuses on innovative ophthalmic therapies for eye diseases, with products like Rhopressa® and Rocklatan® targeting conditions such as glaucoma and ocular hypertension. Further information will be available on its investor relations website.

Positive

• Aerie is scheduled to present Q1 2022 financial results, which could provide insights into revenue growth and business trajectory.

Negative

• None.

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present first quarter 2022 financial results after the market closes Thursday, May 5, 2022.

Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss Aerie’s financial results and provide a general business update.

Details:
Date:			May 5, 2022
Conference call Time:			5:00 p.m. ET
Suggested Dial-in Time			15 minutes prior to ensure time for any required software download
Webcast:			http://investors.aeriepharma.com
US Dial-In option			(888) 734-0328
International Dial-In option			(678) 894-3054
Conference ID			4696464

About Aerie Pharmaceuticals, Inc.

Aerie is a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). Aerie’s first novel product, Rhopressa^® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage. More information about Rhopressa^®, including the product label, is available at www.rhopressa.com. Aerie’s second novel product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan^® (netarsudil (0.02%) and latanoprost ophthalmic solution (0.005%)), was launched in the United States in May 2019. In clinical trials of Rocklatan^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage. More information about Rocklatan^®, including the product label, is available at www.rocklatan.com. More information on Aerie Pharmaceuticals is available at www.aeriepharma.com.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “exploring,” “pursuing” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements in this release include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our commercial franchise and our pipeline, any guidance or timelines and our ongoing and anticipated preclinical studies and clinical trials. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, industry change and other factors beyond our control, and depend on regulatory approvals and economic and other environmental circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We discuss many of these risks in greater detail under the heading “Risk Factors” in the quarterly and annual reports that we file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005492/en/

Media:

Carolyn McAuliffe

cmcauliffe@aeriepharma.com

(949) 526-8733

Investors:

LifeSci Advisors on behalf of Aerie Pharmaceuticals, Inc.

Hans Vitzthum

hans@lifesciadvisors.com

(617) 430-7578

Source: Aerie Pharmaceuticals, Inc.

FAQ

When will Aerie Pharmaceuticals announce its Q1 2022 financial results?

Aerie Pharmaceuticals will announce its Q1 2022 financial results on May 5, 2022.

What time is the Aerie Pharmaceuticals conference call for Q1 2022 results?

The conference call for Q1 2022 results will be held at 5:00 p.m. ET on May 5, 2022.

How can I access the Aerie Pharmaceuticals Q1 2022 conference call?

The conference call can be accessed via their webcast at http://investors.aeriepharma.com.

What are Aerie Pharmaceuticals' main products?

Aerie's main products include Rhopressa® and Rocklatan®, which treat elevated intraocular pressure in glaucoma patients.